We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$630M
1-Year Est. Return
108.65%
This Fund
S&P 500
This Quarter
Est. Return
+3.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.3B
AUM Growth
+$177M
(+16%)
Cap. Flow
+$235M
Cap. Flow
% of AUM
18.05%
Top 10 Holdings %
Top 10 Hldgs %
40.67%
Holding
213
New
103
Increased
34
Reduced
21
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$47.9M |
| 2 |
AbbVie
ABBV
|
+$27.8M |
| 3 |
Johnson & Johnson
JNJ
|
+$18.7M |
| 4 |
LivePerson
LPSN
|
+$16.1M |
| 5 |
AstraZeneca
AZN
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$40.5M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$26.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$12.8M |
| 4 |
Zymeworks
ZYME
|
+$11.6M |
| 5 |
Meta Platforms (Facebook)
META
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.55% |
| 2 | Technology | 7.69% |
| 3 | Industrials | 4.91% |
| 4 | Financials | 2.93% |
| 5 | Consumer Discretionary | 1.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNT
201
DELISTED
Verint Systems
VRNT
| – | – |
-249,301
| Closed | -$8.53M |
|
202
Wave Life Sciences
WVE
$1.09B
| – | – |
-414,959
| Closed | -$3.27M |
|
203
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| – | – |
-300,000
| Closed | -$42.2M |
|
|
YMAB
204
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-131,016
| Closed | -$6.49M |
|
|
205
Zymeworks
ZYME
$1.61B
| – | – |
-245,000
| Closed | -$11.6M |
|
|
TECX
206
Tectonic Therapeutic
TECX
$529M
| – | – |
-54,656
| Closed | -$9.14M |
|
|
ORGS
207
DELISTED
Orgenesis Inc. Common Stock
ORGS
| – | – |
-3,571
| Closed | -$161K |
|
|
DCPH
208
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – |
-103,565
| Closed | -$5.91M |
|
|
CNCE
209
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| – | – |
-384,039
| Closed | -$4.85M |
|
|
DRNA
210
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-216,980
| Closed | -$4.78M |
|
|
ALXN
211
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-60,000
| Closed | -$9.37M |
|
|
IACA
212
DELISTED
ION Acquisition Corp 1 Ltd.
IACA
| – | – |
-150,000
| Closed | -$1.77M |
|
Similar funds
VIM
KCMH
FCFC
BI
PWW
TTSTC
SWP
EIM
Sphera Funds Management's Q1 2021 Portfolio in Review
As of Q1 2021, Sphera Funds Management held 213 positions worth $1.3B, up 16% from $1.13B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Sphera Funds Management deployed $235M of net new capital in Q1 2021, opening 103 new positions and adding to 34 existing holdings. Its largest new stake was Sanofi: 997,900 shares worth $49.4M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 68% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $26.4M trimmed.
- Sphera Funds Management's largest Q1 2021 buy was Sanofi: 997,900 shares worth $49.4M.
- Sphera Funds Management added most to AbbVie in Q1 2021, an estimated $27.8M increase.
- Sphera Funds Management's biggest Q1 2021 reduction was Bristol-Myers Squibb, cutting an estimated $26.4M.
- Sphera Funds Management fully exited Novartis in Q1 2021, selling an estimated $40.5M.
- Sphera Funds Management's ten largest holdings make up 41% of its $1.3B portfolio in Q1 2021.
- Sphera Funds Management opened 103 new positions and closed 43 in Q1 2021.
- Sphera Funds Management's portfolio value rose 16% quarter-over-quarter to $1.3B.
Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.